Top Page
Physiomics
(LSE:PYC)
Physiomics (PYC) vs. iShares MSCI United Kingdom ETF (EWC)
Physiomics Business Overview & Revenue Model
Physiomics Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 517.56K | 543.25K | 597.35K | 830.27K | 702.31K | 799.05K |
| Gross Profit | -688.12K | -677.43K | -581.62K | -429.01K | -365.79K | -177.15K |
| EBITDA | -674.37K | -659.80K | -561.57K | -347.84K | -324.52K | -124.71K |
| Net Income | -634.35K | -609.35K | -477.26K | -253.14K | -215.83K | -64.42K |
Balance Sheet | ||||||
| Total Assets | 1.41M | 422.60K | 674.39K | 1.12M | 1.32M | 1.45M |
| Cash, Cash Equivalents and Short-Term Investments | 1.15M | 191.07K | 416.59K | 687.67K | 1.04M | 1.05M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 122.00K | 140.08K | 142.67K | 140.61K | 157.57K | 131.52K |
| Stockholders Equity | 1.29M | 282.53K | 531.72K | 974.81K | 1.17M | 1.31M |
Cash Flow | ||||||
| Free Cash Flow | -497.44K | -565.44K | -271.50K | -358.62K | -48.65K | -120.78K |
| Operating Cash Flow | -480.13K | -548.13K | -264.86K | -349.25K | -32.50K | -115.69K |
| Investing Cash Flow | -16.21K | -15.21K | -6.22K | -9.37K | -16.15K | -5.09K |
| Financing Cash Flow | 362.83K | 337.83K | 0.00 | 2.85K | 44.24K | 763.28K |
Physiomics Technical Analysis
Physiomics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$15.54B | 5.54 | -7.44% | 4.07% | 11.55% | -28.15% | |
58 Neutral | £373.60M | ― | -66.23% | ― | 43.84% | 74.88% | |
47 Neutral | £25.54M | ― | -87.30% | ― | ― | 71.17% | |
46 Neutral | £106.27M | ― | 167.16% | ― | -100.00% | -23.91% | |
42 Neutral | £123.77M | ― | -73.02% | ― | ― | ― | |
38 Underperform | £1.44M | ― | -116.39% | ― | -21.33% | -2.50% |
Physiomics Corporate Events
Physiomics plc has secured a new contract with a UK client to apply its modelling and simulation techniques in the development of a bifunctional antibody therapy targeting multiple solid tumor indications. This project, valued at £47,600, will utilize pharmacokinetic modelling to predict human PK and support the client’s first-in-human study. The contract signifies Physiomics’ progress in expanding its client base and enhancing its role in developing oncology therapies.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics faces substantial financial and technical challenges, reflected in declining revenues and bearish technical indicators. Recent corporate events provide some optimism for future growth, but current valuation issues and financial instability weigh heavily on its stock score.
To see Spark’s full report on GB:PYC stock, click here.
Physiomics plc has announced the publication of a peer-reviewed article in collaboration with Ankyra Therapeutics, detailing a pharmacokinetic and pharmacodynamic model for an interleukin-12 anchored-drug conjugate aimed at treating solid tumors. This publication highlights the growing importance of mathematical modelling in drug development, showcasing Physiomics’ capability to support successful drug development programs and its strong positioning in the market amid increasing regulatory pressures.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics faces substantial financial and technical challenges, reflected in declining revenues and bearish technical indicators. Recent corporate events provide some optimism for future growth, but current valuation issues and financial instability weigh heavily on its stock score.
To see Spark’s full report on GB:PYC stock, click here.
Physiomics plc has secured a new contract with Numab Therapeutics AG to apply modelling and simulation techniques in the pre-clinical development of a multi-specific antibody aimed at activating anti-tumor immune responses for cancer treatment. This collaboration underscores Physiomics’ role as a trusted partner in drug development, enhancing its industry positioning and reinforcing its long-term relationship with Numab Therapeutics.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics faces significant financial and technical challenges, with declining revenues and bearish technical signals. While recent corporate events indicate potential future growth, current valuation concerns and financial instability weigh heavily on its stock score.
To see Spark’s full report on GB:PYC stock, click here.
Physiomics plc has secured a new contract with a UK-based biotech company focused on antibody drug conjugates (ADCs) for treating difficult cancers. This project, valued at £102,000, involves developing a Pharmacokinetic (PK) Pharmacodynamic (PD) model to optimize dosing for the client’s upcoming First-in-Human trial, running from April to August 2025. The contract reflects Physiomics’ strategy to diversify its client base and expand into new therapeutic areas, enhancing its industry positioning in the oncology treatment sector.
Physiomics plc has updated its website with a recent presentation and Q&A session from its Interim Results meeting, accessible via their website. This update aims to provide stakeholders with insights into the company’s current operations and strategic direction, potentially impacting its market positioning and stakeholder engagement.
Physiomics plc reported interim financial results for the six-month period ending December 31, 2024, showing a slight decrease in revenue and an increase in operating loss compared to the previous year. Despite these financial challenges, the company has established a strong pipeline with new contracts and expanded its service offerings, including the launch of a Biostatistics service line and the development of Personalized Medicine Dosing Software. The company completed a successful fundraising effort, enhancing its cash position, and is on track to meet market expectations for the year, driven by a robust second half and strategic growth initiatives.
Physiomics plc announced it will release its interim results on March 6, 2025, followed by a live investor presentation on March 10, 2025. This presentation, led by CEO Peter Sargent and Chairman Jim Millen, will be open to existing and potential shareholders, providing an opportunity to discuss the interim results and broader business aspects. This initiative reflects Physiomics’ commitment to transparency and engagement with its stakeholders, potentially enhancing its industry positioning and investor relations.
Physiomics PLC has announced a change in major holdings, indicating a shift in the company’s shareholder structure. Ryan Mancrief has sold his holdings at Barclays Investment Solutions Limited, now holding 14,234,711 shares in a nominee account at AJ Bell plc, which represents 4.6947% of the company’s issued share capital. This change reflects a decrease from a previous position of 8.5127% and may impact the company’s voting dynamics and influence among stakeholders.
Physiomics plc announced the successful completion of its WRAP Retail Offer, raising £70,000, which combined with a previous placing, totals £500,000 in gross proceeds. The funds will support the company’s growth, including recruitment for its consulting services, investment in business development, and the expansion of its personalized medicine tools, signifying an effort to bolster its industry position and service offerings.
Physiomics plc has announced a retail offer via the Winterflood Retail Access Platform to raise up to £70,000 through the issuance of new ordinary shares. This offer is part of a broader strategy to raise approximately £500,000 through a separate placing of new shares. The funds raised will support the company’s ongoing operations and strategic initiatives. The offer is targeted exclusively at existing retail shareholders in the UK, emphasizing the company’s commitment to its retail shareholder base. The offer is not contingent upon the completion of the separate placing, ensuring flexibility in capital acquisition. This initiative reflects Physiomics’ strategic approach to strengthening its financial position and enhancing shareholder value.
Physiomics plc has successfully completed a £430,000 placing to fund growth opportunities, issuing 86,000,000 new ordinary shares at a 37.5% discount. The company is also launching a retail offer to raise an additional £70,000. The funds will support the recruitment of technical staff, business development, and strategic growth in their consulting services. The company has made progress with new contract awards and publications, and aims to further its personalized medicine tools in collaboration with DoseMe. Recent achievements include contract wins and high-profile collaborations, positioning the company for continued growth and new business opportunities in the biotech and pharma sectors.